Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 29 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

The trial met its primary endpoint, showing a significant treatment difference in patients achieving a meaningful biochemical response compared to placebo. Zydus Therapeutics plans to submit a regulatory application for Saroglitazar in the U.S. in the first quarter of the following year. The press release emphasizes the potential of Saroglitazar as a new treatment option for patients who have not responded to standard therapies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 29, 2025, titled "Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases